Evaxion A/S (NASDAQ:EVAX) Announces Earnings Results, Misses Estimates By $0.09 EPS

Evaxion A/S (NASDAQ:EVAX) released its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.09), FiscalAI reports.

Evaxion A/S Price Performance

Shares of EVAX opened at $3.15 on Thursday. The firm’s 50-day simple moving average is $3.14 and its 200 day simple moving average is $3.56. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. The firm has a market cap of $26.27 million, a P/E ratio of -2.14 and a beta of 0.29. Evaxion A/S has a 52 week low of $2.52 and a 52 week high of $12.15.

Hedge Funds Weigh In On Evaxion A/S

An institutional investor recently bought a new stake in Evaxion A/S stock. SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,194 shares of the company’s stock, valued at approximately $72,000. SmartHarvest Portfolios LLC owned 0.18% of Evaxion A/S at the end of the most recent quarter. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on EVAX shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Friday, April 24th. Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.